NCT04329975View on ClinicalTrials.gov

Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia)

CompletedOBSERVATIONAL
Enrollment

1,087

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

September 25, 2024

Study Completion Date

September 25, 2024

Conditions
Nocturia Due to Nocturnal Polyuria
Interventions
DRUG

Desmopressin

Desmopressin (MINIRINMELT OD tablet) 25μg or 50μg, orally.

Trial Locations (1)

Unknown

Survey Site (there may be other sites in this country), Tokyo

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT04329975 - Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia) | Biotech Hunter | Biotech Hunter